anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Latinos are the fastest growing ethnic group of the U.S. with a growth rate of 43% compared to 23% among whites over the past decade. This increase is four times the nation's 9.7% growth rate, and accounts for more than half of the total U.S. population increase of 27.3 million during this period. This growth is accompanied by a significant increase in cardiovascular disease (CVD)-related morbidity and mortality. Despite increasing trends in the awareness and treatment of hypertension (HTN) among all groups, Latinos have the lowest blood pressure (BP) control rates in the U.S. Although barriers to optimal HTN control such as poor access, and low awareness have been used to explain the disparities in BP control between Latinos and whites, BP control rates remain lower among Latinos who receive treatment compared to whites. This enigma may be explained by the disproportionately poorer adherence to prescribed antihypertensive medications among Latinos compared to whites. Poor medication adherence is a major contributor to inadequate BP control, and is associated with 125,000 deaths annually. Despite over 30 years of research dedicated to understanding adherence behaviors in hypertensive patients, data in Latino patients is scant. More importantly, translation of adherence interventions to community-based primary care practices where majority of Latino patients receive care is non-existent.
PURPOSE:To obtain the titled plaster, having excellent water resistance, capable of releasing the drug continuously for a long period, and having low side effects, by applying a stretchable polymer film impermeable to the drug to be fused and integrated, to one surface of a stretchable nonwoven cloth. CONSTITUTION:A stretchable polymer film impermeable to a drug (e.g. copolymer of acrylonitrile and acrylic acid ester) is applied to a surface of a stretchable nonwoven cloth. A copolymer of (i) an alkyl (meth) acrylate, (ii) a (meth) acylic acid ester having ether group in the molecule and (iii) a polar monomer is compounded with an anti-inflammatory analgesic agent (e.g. diclofenac sodium), and the mixture is applied as a drug-releasing adhesive layer to the film surface of the above laminate. Since of the drug compounded in the adhesive layer is not absorbed to the nonwoven cloth, and the water-resistance is improved, the plaster is resistant to release from the skin even after immersing in water, and an environment suitable for the release of the drug can be attained by the supply of a proper amount of water.
The present invention is related to topical preparations for release of an active agent and to methods of making and using the topical preparations. The preparations may have an internal phase dispersed within an external phase. The internal phase may be a hydrophilic carrier and an active agent. The external phase may be a silicone matrix. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that is will not be used to interpret or limit the scope or meaning of the claims.
<P>PROBLEM TO BE SOLVED: To provide a use of a tumor-suppressing gene in combination with a DNA injuring agent or a DNA injuring factor, for killing cells, in particular carcinoma cells.  <P>SOLUTION: A tumor-suppressing gene p53 in combination with a chemotherapeutical agent is transferred by a gene transfer through a recombinant adenovirus both in vitro and in vivo. The cells to be treated are subjected to an apoptosis along with a specific fragmentation of DNA. A direct hypodermic injection of p53 adenovirus build-up into the tumor and a subsequent abdominal administration of a cisplatin that is a DNA injuring agent lead to a large scale apoptotic destruction of the tumor. The present invention provides a clinical application of a resume that combines a gene replacement using a copying function-defective wild type p53 adenovirus and a DNA injuring agent for treatment of a human cancer.  <P>COPYRIGHT: (C)2004,JPO
These patients are young children (\<5 years of age) with newly diagnosed high-risk embryonal CNS malignancies and are expected to have a modest male predominance reflecting the sex-based incidence of pediatric brain tumors. Patients will have a Lansky performance status of ≥60.
A system for pandemic and connection tracking is provided. The system includes a memory and one or more processors in communication with the memory, and a data collector executing on the one or more processors. The data collector is configured to collect anonymous tracking data from a wireless sensor network. The wireless sensor network is configured to communicate with users' devices using a wireless connection. The system further includes a data validator/augmentor executing on the one or more processors. The data validator/augmentor is configured to validate the collected anonymous tracking data. The system also includes a virus spread tracker executing on the one or more processors. The virus spread tracker is configured to: estimate an exposure time between each pair of users based on the collected anonymous tracking data; and determine a probability of at least one of the users being infected based on the estimated exposure time.
OBJECTIVE: This study aimed to investigate the changes in angiopoietin-2 and tumor necrosis factor α levels in patients with acute myocardial infarction complicated with pulmonary infection.
METHODS: Retrospective selection was conducted on 61 patients with acute myocardial infarction complicated with pulmonary infection and 122 patients with simple acute myocardial infarction. A comparison was made between the two groups regarding general information and serum myocs. The distribution and drug resistance of pathogenic bacteria were also explored.
RESULTS: The study showed significant differences in the duration of alcohol consumption, the proportion of diabetes mellitus, and levels of certain markers (serum cardiac troponin T, creatine kinase isoenzyme, myoglobin, angiopoietin-2, tumor necrosis factor α) between the two groups (P < .05). Logistic regression analysis identified elevated levels of serum angiopoietin-2 and tumor necrosis factor α, along with diabetes mellitus, as independent risk factors for acute myocardial infarction complicated with pulmonary infection (P < .05). Pearson correlation analysis demonstrated a positive correlation between serum angiopoietin-2 and tumor necrosis factor α levels and CPI scores in patients (P < .05). ROC curve analysis indicated that combined diagnosis of serum angiopoietin-2 and tumor necrosis factor α had an AUC of 0.867, with a sensitivity of 85.25% and specificity of 77.87% for detecting acute myocardial infarction complicated with pulmonary infection. Among the sputum culture specimens, gram-negative bacteria accounted for 55.34%, gram-positive bacteria for 39.81%, and fungi for 4.85%. Gram-negative bacteria like Klebsiella pneumoniae and Escherichia coli showed high resistance to various antibiotics, while gram-positive bacteria like Streptococcus pneumoniae and Staphylococcus aureus had relatively low resistance to specific antibiotics.
CONCLUSION: Gram-negative bacteria were the main pathogens and exhibited resistance to several antibiotics. Increased levels of angiopoietin-2 and tumor necrosis factor α were observed. Early detection of these markers can assist in the clinical diagnosis and guide the appropriate use of antibiotics.
Embodiments provide an improved healthcare system that includes a two-tiered healthcare cryptocurrency used to digitally execute healthcare payment transactions between consumers and healthcare provides. The embodiments are directed to systems and methods for executing the healthcare payment transactions using the two-tiered healthcare cryptocurrency. The systems and methods deposit, by a healthcare service application, a sum of healthcare cryptocurrency to the healthcare service account of the user. The systems and methods receive by the user from a healthcare provider, through a user interface to the healthcare service application, a payment request for a health related service in a specified amount of the healthcare cryptocurrency. The systems and methods transmit by the user to the healthcare provider, through the user interface, a confirmation of the payment request in the specified amount. The systems and methods transfer, by the healthcare service application, the specified amount from the healthcare service account of the user to the healthcare service account of the healthcare provider. The systems and methods record, by the healthcare service application, the given health related service, the healthcare provider, and the specified amount in the blockchain.
Most children with a rare disease are cared for by their family members but parenting such a child is extremely demanding due to the complexity and severity of symptoms, with serious physical, emotional, social, and financial consequences for caregivers. Although religion may serve as a positive coping strategy, little is known about its role in helping caregivers manage the stress related to the burden of caregiving in Poland. Therefore, we surveyed 925 Polish family caregivers of children with rare diseases to understand the association between caregivers' religiosity and their caring experiences. The findings suggest that parents' religiosity is associated with a more positive caregiving experience, perceived quality of life, and experienced caregiving burden. While religious caregivers reported experiencing less distressing emotions and stressed the encouraging impact of their child's disease on their life more often, non-religious caregivers experienced role captivity and role overload more frequently. Since religion may serve as a source of strength and a protecting factor against mental health problems and the burden of caregiving, healthcare professionals should be aware of the importance of religious and spiritual care, and caregivers' religiosity should be considered an integral part of a holistic approach.
The invention relates to a traditional Chinese liniment of external application which is used for the treatment of apoplexy and flaccid paralysis, namely Bingma ointment. The traditional Chinese liniment is prepared by the following components by weight ratio: 2.7g to 3.2g of borneol, 5.8g to 6.3g of nux vomica and 6g to 8g of egg white. The borneol and the nux vomica are ground to fine powders and then mixed well with the egg white to form an ointment shape for being applied on the corresponding acupuncture points. According to a traditional meridian Shu-acupoint theory of Chinese medicine and a modern transdermal treatment theory, the two drugs are combined for being applied on the corresponding acupuncture points to obtain obvious therapeutic effectiveness through clinical trial. The traditional Chinese liniment has the efficacies of removing obstruction in the channels and eliminating stagnation, detumescence and analgesic therapy, curing impotence as well as inducing resuscitation and awakening the spirit. The traditional Chinese liniment is pasted on the corresponding acupuncture points for external application, characterized by convenient usage, obvious therapeutic effectiveness, low cost, pleased acceptance of sufferers and the like.
High-risk human papillomavirus (HR-HPV) testing, utilizing both DNA and RNA methods, offers enhanced sensitivity compared to cytology for detecting high-grade cervical intraepithelial neoplasia (CIN2+). Meanwhile, HR-HPV E6 and E7 mRNAs are more likely to differentiate the transient infection from the persistent than DNA. Aptima HPV can not only detect HPV mRNA but also HPV DNA though it is much more efficient at detecting HPV RNA than DNA. Currently, there are few studies on the distribution of HPV E6 and E7 mRNA and DNA in the same individual. It is interesting to compare the clinical performance of the Onclarity and Aptima HPV assays and to assess variations in viral load across different histological grades at both DNA and mRNA levels. The analysis included 1607 women (902 from a cervical cancer screening population and 705 inpatients and outpatients), with cervical cytological samples tested using the Aptima and Onclarity HPV assays. Both assays demonstrated high agreement for HPV types 18/45 and 16. Signal-to-cutoff (S/CO) values and Ct values for various HR-HPV types increased with histological severity from normal tissue to cancer. Notably, HPV18 Ct values exceeded those for HPV16 and 45 in women with ≥ CIN1 lesions but decreased sharply in cancer cases. Across the screening population, both assays showed similar sensitivity and predictive values for detecting CIN2+ lesions. The area under the curve (AUC) for CIN2+ and CIN3+ detection in the study population was robust (CIN2+: 0.880, 0.863; CIN3+: 0.881, 0.863). The DNA level for various HR-HPV types increased with histological severity from normal tissue to cancer, which might impact the performance of Aptima HPV assay. Both assays showed similar sensitivity and predictive values for detecting CIN2+ lesions.
The overarching objective of this observational prospective Family Risk \& Lung Cancer Study is to evaluate the impact of a loved one s lung cancer diagnosis on relative s seeking and processing of information related to risks of smoking, genetic susceptibility, and their receptivity to smoking cessation services. We plan to recruit 150 relatives of lung cancer patients who are receiving care at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. First- or second-degree blood relatives who are current smokers between the ages 18 to 55 will be eligible for the study. Because these relatives will be living throughout the United States, a web-based research protocol will be employed. A nurse recruiter will approach patients at Moffitt and assess their willingness to do a telephone survey to enumerate their relatives who smoke and be asked to give permission to contact none, some or all of these relatives. These survey contacts with patients and contacts with relatives for screening and recruitment will be conducted in partnership with an ongoing recruitment activities for a five-year, NCI-funded randomized controlled intervention trial (RCT) at Duke University Medical Center (Quit Smoking Program for Lung Cancer Patient s Families or Family Ties ; Duke IRB# 4620, Bastian, PI). Relatives who agree to participate will be asked to log on to a password protected website and view two online educational sessions and complete three online surveys. As part of the educational session, participants will be offered free genetic susceptibility testing for glutathione S transferase (GSTM1). Participants who accept testing will receive their result online. Participants who decline testing will be retained in the study and offered all the same smoking cessation services provided to those who accept testing. Participants will be sent instructions to collect their own buccal samples and postage-paid mailing envelopes to return the sample to a CLIA-approved laboratory at Duke. Survey assessments will include questions about risk perceptions, beliefs and attitudes related to lung cancer, emotional responses to the patient s diagnosis, smoking history, motivation to quit, reactions to information about smoking and genetic risk, interest in genetic testing, comprehension of susceptibility feedback, and interest in receiving smoking cessation services. The primary outcome variable will be seeking of free quit smoking services. Participating relatives will be surveyed by telephone via the Duke RCT infrastructure 6-months after completing the online protocol.
Post-ERCP pancreatitis (PEP) is an acute pancreatitis caused by endoscopic-retrograde-cholangiopancreatography (ERCP). About 10% of patients develop PEP after ERCP. Here we show that gamma-glutamyltransferase 1 (GGT1)-SNP rs5751901 is an eQTL in pancreatic cells associated with PEP and a positive regulator of the IL-6 amplifier. More PEP patients had the GGT1 SNP rs5751901 risk allele (C) than that of non-PEP patients at Hokkaido University Hospital. Additionally, GGT1 expression and IL-6 amplifier activation were increased in PEP pancreas samples with the risk allele. A mechanistic analysis showed that IL-6-mediated STAT3 nuclear translocation and STAT3 phosphorylation were suppressed in GGT1-deficient cells. Furthermore, GGT1 directly associated with gp130, the signal-transducer of IL-6. Importantly, GGT1-deficiency suppressed inflammation development in a STAT3/NF-κB-dependent disease model. Thus, the risk allele of GGT1-SNP rs5751901 is involved in the pathogenesis of PEP via IL-6 amplifier activation. Therefore, the GGT1-STAT3 axis in pancreas may be a prognosis marker and therapeutic target for PEP.
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative central nervous system (CNS) disorder, characterized by focal inflammation, demyelination, irreversible axonal loss and neurodegeneration. The proposed mechanism involves auto-reactive T lymphocytes crossing the blood-brain barrier (BBB), contributing to inflammation and demyelination. Pro-inflammatory Th1 and Th17 lymphocytes are pivotal in MS pathogenesis, highlighting an imbalanced interaction with regulatory T cells. Dysbiosis in the gut microbiota, characterized by microbial imbalance is implicated in systemic inflammation, yet its exact role in MS remains elusive. Short-chain fatty acids (SCFAs), including valerate, butyrate, propionate, and acetate, produced through dietary fiber fermentation by the gut microbiota, modulate inflammation and immune responses. Particularly, butyrate and propionate exhibit pronounced anti-inflammatory effects in both the gut and CNS. These SCFAs influence regulatory T lymphocyte expression and BBB permeability. This review discusses the potential therapeutic implications of SCFA in MS, highlighting their ability to modulate the gut-brain axis and restore immune balance.
The importance of the common cold derives primarily from its frequency and from its enormous socioeconomic impact. Human Rhinoviruses (HRVs) are the major cause of the common cold, being responsible for 30-50% of all acute respiratory illnesses with no causal remedies at hand. A model to investigate the pathophysiology of HRV infection and to test compounds that could treat or protect one from infection or developing symptoms would therefore be very valuable. With this HRV model it is also possible to investigate crosstalk between bacteria and viruses. This is very relevant because, following a viral infection, bacterial superinfections are common in clinical practice, and underlying mechanisms and subsequent possible therapies that could prevent this remain to be discovered. Worldwide, thousands of subjects have been exposed to experimental rhinovirus infection, of which more than 600 to HRV-16. Serious adverse events related to rhinovirus infection have never been documented. Therefore, this model can be considered a safe and highly reproducible model. Moreover, 52 volunteers have already been exposed to the HRV-16 virus from the batch that we want to use in this study.

Healthy volunteers who meet all inclusion criteria and none of the exclusion criteria that have given informed consent to participate in the study will be randomized to become either inoculated with HRV-16 (n=20; 10 male+10 female) or with placebo (saline 0.9%, n=20, 10 male+ 10 female). After one week a second inoculation with HRV-16 will be performed in both groups. In both groups, 50% of the subjects will be sero-negative and 50% sero-positive to HRV-16. One hundred TCID50 units of HRV-16 (by spraying 0.5 mL into each nostril in supine position in a randomized manner) will be administered.

The main study parameter is the rate of infection (defined by a positive viral culture, qPCR and/or a four-fold rise in antibody titre) caused by HRV-16 inoculation. Secondary endpoints include the duration of the incubation period, the effects of HRV-16 (re-)infection on cold symptoms and spirometry, kinetics of HRV-16-induced local inflammation parameters in nasal washes (including immune cells and cytokine production), kinetics of the HRV-16-induced systemic immune response (including circulating cytokines), the ability of HRV to modulate the systemic immune response (as reflected by the ex vivo production of inflammatory mediators by stimulated leukocytes), the effects of seropositivity on clinical and immunological responses, and the effects of HRV-16 infection on faecal and nasal-pharyngeal microbiota and host transcriptome and metabolome.
Fifty, (50) children will be provided CBD as part of the Principal Investigator's Physician Expanded Access IND. CBD will be administered as an adjunct to all current antiepileptic drugs. After the screening visit, a 4 week baseline period will be followed and seizures will be recorded in the seizure diary given to the patient at this time. The patients will be clinically evaluated at baseline, once a month for three months and once every three months thereafter. For the first week after study initiation, patients will be called at day 3 to review any changes in condition and again at day 7 to review any changes in condition and to determine whether an increase in dosing is required. Subsequently, patients will be called each week during the titration period to review any changes in condition and determine whether an increase in dosing is required. Maximal dose titration should be achieved in most patients within 5 weeks. In order to ensure safe use at higher doses, patients who receive more than 600 mg of daily CBD will be evaluated at least monthly until they achieve steady state at their final fixed maintenance dose. The investigator will be available by telephone or email throughout the initial four months of the study in between the visits.
The subjects received fluvoxamine (immediate release) 50 mg, 1 tablet in the morning and 50 mg 2 tablets before bedtime, orally after meals. For a total of 14 days, the first two days and the last two days, 50 mg 1 tablet in the morning and 50 mg 1 tablet at bedtime. Co- administration with cyproheptadine 4 mg, 1 tablet, three times, orally after meals and should be taken every 8 hours apart, for 14 days.
This arm will receive the pedometer intervention, which will include attending 3 monthly UTMB Breast Cancer Support Group sessions, and monitor daily, weekly, and monthly steps using a pedometer (Digit-Walker CW-700/701). All participant will be provided a water bottle and a tote bag as a token of appreciation for participation.
FIELD: analytical biochemistry, polymers. SUBSTANCE: invention proposes new sorbent for affinity assay of the glycosylated hemoglobin. High effectiveness of sorbent by ligand (above 20-fold use of 1 ml sorbent) is provided by the presence of cross-linked polyvinyl alcohol with the immobilized m-aminophenylboronic acid of the general formula given in description where amount of m-aminophenylboronic acid in sorbent is 0.37-1.49%, molecular mass of an active chain of cross-linked polyvinyl alcohol is 2·I0 3 ÷3·I0 3 , Da, swelling coefficient is 80-100%. Sorbent can be used in medicine for diagnosis and course severity of diabetus mellitus. EFFECT: improved quality and property of sorbent. 3 tbl
Oral administration of a single pill of celecoxib (200 mg). Celecoxib pills will be over-encapsulated to match the placebo.